Termeer-backed ProQR lays out terms for $75M IPO

The Dutch biotech ProQR, which has rounded up cash from a group of backers that includes former Genzyme CEO Henri Termeer, has laid out its proposed terms for a $75 million IPO. The biotech, which is focused on the role of messenger RNA in cystic fibrosis, plans to sell 6.3 million shares at $11 to $13 a share. The company, which is tackling the same patient population as Boston-based Vertex ($VRTX), has plans to file an IND on its lead drug later this year. After that Termeer and his group of well-connected biotech execs who are advising the company--which includes Dinko Valerio, the former CEO of J&J's ($JNJ) Crucell--expect to take the program all the way through to commercialization. Story

Suggested Articles

Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.

Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.

Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.